The FDA Modernization Act 2.0 | DefiniGEN
The new FDA Modernization Act 2.0 authorizes the use of certain alternatives to animal testing, including cell-based assays, to investigate the safety and effectiveness of a drug.
DefiniGEN’s vision is to provide highly predictive cell-based models of liver disease to the drug development industry. These models will be used to reduce the chances of a medicine failing at the clinical stage and reduce the number of animals used in safety assessment.